D.A. Davidson & CO. trimmed its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 0.2% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 167,648 shares of the pharmaceutical company’s stock after selling 274 shares during the quarter. D.A. Davidson & CO.’s holdings in GlaxoSmithKline PLC were worth $7,228,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Carroll Financial Associates Inc. lifted its position in shares of GlaxoSmithKline PLC by 0.4% during the 2nd quarter. Carroll Financial Associates Inc. now owns 8,690 shares of the pharmaceutical company’s stock valued at $374,000 after acquiring an additional 35 shares during the period. King Luther Capital Management Corp lifted its position in shares of GlaxoSmithKline PLC by 1.0% during the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock valued at $234,000 after acquiring an additional 55 shares during the period. First National Bank of Omaha lifted its position in shares of GlaxoSmithKline PLC by 0.3% during the 2nd quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company’s stock valued at $827,000 after acquiring an additional 57 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in shares of GlaxoSmithKline PLC by 1.9% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after acquiring an additional 64 shares during the period. Finally, Baystate Wealth Management LLC lifted its position in shares of GlaxoSmithKline PLC by 1.4% during the 2nd quarter. Baystate Wealth Management LLC now owns 5,520 shares of the pharmaceutical company’s stock valued at $233,000 after acquiring an additional 75 shares during the period. Hedge funds and other institutional investors own 9.28% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline PLC (GSK) Stake Decreased by D.A. Davidson & CO.” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-stake-decreased-by-d-a-davidson-co/1576019.html.

Shares of GlaxoSmithKline PLC (NYSE GSK) traded up 0.313% during trading on Wednesday, reaching $40.045. The company’s stock had a trading volume of 890,872 shares. The stock’s 50-day moving average is $39.76 and its 200-day moving average is $41.75. The stock has a market cap of $97.87 billion, a P/E ratio of 39.570 and a beta of 1.03. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last issued its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities research analysts anticipate that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be given a dividend of $0.491 per share. The ex-dividend date of this dividend is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.92%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 197.00%.

A number of analysts have recently weighed in on GSK shares. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research report on Tuesday, July 18th. Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Argus reiterated a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. TheStreet downgraded GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Finally, ValuEngine downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $46.00.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.